Glew R H, Daniels L B, Clark L S, Hoyer S W
J Neuropathol Exp Neurol. 1982 Nov;41(6):630-41. doi: 10.1097/00005072-198211000-00006.
This study explores the biochemical basis that may distinguish neurologic and nonneurologic forms of Gaucher's disease. Crude membrane preparations from spleens of controls and patients representing the three clinical categories of Gaucher's disease were delipidated by extraction with sodium cholate and n-butanol. Total beta-glucosidase activity was estimated using 4-methylumbelliferyl-beta-D-glucopyranoside (MUG) as substrate, and glucocerebrosidase activity was determined using (3H)-glucocerebroside. beta-Glucosidase and glucocerebrosidase activities were reconstituted by inclusion of sodium taurocholate or phosphatidylserine in the assay medium. When assays contained phosphatidylserine, residual beta-glucosidase activity in delipidated spleen preparations from type 1, nonneurologic cases were five times greater than cases of neurologic Gaucher's disease (82.3 vs. 11.3 units per mg protein). However, beta-glucosidase assays using sodium taurocholate did not discriminate Gaucher's disease subtypes. Similar results were obtained when spleen preparations were analyzed for glucocerebrosidase using glucocerebroside as the substrate. Brain beta-glucosidase from patients representing the three classes of Gaucher's disease showed a similar pattern of sensitivity toward phosphatidylserine. The specific activity of beta-glucosidase in an extract of brain from the one case of type 1 Gaucher's disease analyzed was five times greater than the mean residual specific activity of brain beta-glucosidase measured in five cases of type 2 and type 3 Gaucher's disease. These findings suggest that, in patients with type 1 Gaucher's disease, glucocerebrosidase may show greater activity in the presence of acidic phospholipids than glucocerebrosidase does in patients with neurologic forms of the disease. The ability of the brain enzyme from a type 1 case to be profoundly stimulated by an acidic phospholipid may explain why such individuals are spared central nervous system involvement.
本研究探索了可能区分戈谢病神经型和非神经型的生化基础。通过用胆酸钠和正丁醇萃取,对代表戈谢病三种临床类型的对照者和患者脾脏的粗制膜制剂进行脱脂处理。使用4-甲基伞形酮基-β-D-吡喃葡萄糖苷(MUG)作为底物估计总β-葡萄糖苷酶活性,使用(3H)-葡萄糖脑苷脂测定葡萄糖脑苷脂酶活性。通过在测定介质中加入牛磺胆酸钠或磷脂酰丝氨酸来重建β-葡萄糖苷酶和葡萄糖脑苷脂酶活性。当测定含有磷脂酰丝氨酸时,1型非神经型戈谢病患者脱脂脾脏制剂中的残余β-葡萄糖苷酶活性比神经型戈谢病患者高五倍(每毫克蛋白质82.3单位对11.3单位)。然而,使用牛磺胆酸钠的β-葡萄糖苷酶测定无法区分戈谢病亚型。当使用葡萄糖脑苷脂作为底物分析脾脏制剂中的葡萄糖脑苷脂酶时,得到了类似的结果。代表戈谢病三种类型的患者的脑β-葡萄糖苷酶对磷脂酰丝氨酸表现出相似的敏感性模式。分析的1例1型戈谢病患者脑提取物中β-葡萄糖苷酶的比活性比在5例2型和3型戈谢病患者中测得的脑β-葡萄糖苷酶平均残余比活性高五倍。这些发现表明,在1型戈谢病患者中,酸性磷脂存在时葡萄糖脑苷脂酶的活性可能比神经型疾病患者中的葡萄糖脑苷脂酶活性更高。1例1型患者的脑酶受酸性磷脂深度刺激的能力可能解释了为什么这些个体没有中枢神经系统受累。